Citadel Advisors’s ESSA Pharma EPIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-14,900
| Closed | -$2.85K | – | 12990 |
|
|
2025
Q3 | $2.85K | Sell |
14,900
-13,700
| -48% | -$16.4K | ﹤0.01% | 12584 |
|
|
2025
Q2 | $48.6K | Sell |
28,600
-13,700
| -32% | -$23.1K | ﹤0.01% | 11783 |
|
|
2025
Q1 | $66.8K | Buy |
42,300
+18,200
| +76% | +$30.8K | ﹤0.01% | 11977 |
|
|
2024
Q4 | $43.1K | Buy |
24,100
+23,400
| +3,343% | +$74.5K | ﹤0.01% | 12544 |
|
|
2024
Q3 | $4.24K | Sell |
700
-3,900
| -85% | -$21.4K | ﹤0.01% | 13586 |
|
|
2024
Q2 | $24.2K | Sell |
4,600
-1,700
| -27% | -$10.8K | ﹤0.01% | 12472 |
|
|
2024
Q1 | $53.5K | Sell |
6,300
-600
| -9% | -$5.24K | ﹤0.01% | 12113 |
|
|
2023
Q4 | $45.5K | Sell |
6,900
-1,700
| -20% | -$8.38K | ﹤0.01% | 11874 |
|
|
2023
Q3 | $26.6K | Buy |
8,600
+4,300
| +100% | +$12.4K | ﹤0.01% | 12384 |
|
|
2023
Q2 | $11.6K | Sell |
4,300
-10,200
| -70% | -$29.9K | ﹤0.01% | 13132 |
|
|
2023
Q1 | $43.1K | Sell |
14,500
-9,400
| -39% | -$27.6K | ﹤0.01% | 12356 |
|
|
2022
Q4 | $60.2K | Sell |
23,900
-15,100
| -39% | -$43.3K | ﹤0.01% | 11910 |
|
|
2022
Q3 | $71K | Buy |
39,000
+21,900
| +128% | +$57.7K | ﹤0.01% | 11369 |
|
|
2022
Q2 | $54K | Sell |
17,100
-4,500
| -21% | -$25.1K | ﹤0.01% | 11888 |
|
|
2022
Q1 | $133K | Buy |
21,600
+10,200
| +89% | +$89.7K | ﹤0.01% | 11980 |
|
|
2021
Q4 | $162K | Buy |
+11,400
| New | +$127K | ﹤0.01% | 12166 |
|
Citadel Advisors's EPIX Position: Q4 2025 in Review
Citadel Advisors sold out of ESSA Pharma (EPIX) in Q4 2025, closing a stake of 144,449 shares — an estimated $27.6K sold.
Citadel Advisors first reported a position in EPIX in Q2 2017 and held it in 20 quarters. The position peaked at $20.6M in Q2 2021. 0 funds tracked by Wall St. Rank hold EPIX as of Q4 2025.
- Citadel Advisors reported no remaining ESSA Pharma position as of Q4 2025 after selling out during the quarter.
- Citadel Advisors sold 144,449 ESSA Pharma shares in Q4 2025, an estimated $27.6K.
- Citadel Advisors first reported a position in ESSA Pharma in Q2 2017 and held it in 20 quarters.
- Citadel Advisors's ESSA Pharma position peaked at $20.6M in Q2 2021.
- 0 funds tracked by Wall St. Rank held ESSA Pharma as of Q4 2025.
Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.